The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
When patients and physicians disagree on the use of genetic engineering technology, physicians must act in accordance with professional ethics and society's guidelines.